France· FR:68234294
PLUVICTO 1 000 MBq/mL, solution injectable/pour perfusion
A medicinal product containing lutécium (177lu) vipivotide tétraxétan, registered in France by NOVARTIS EUROPHARM (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LUTÉCIUM (177LU) VIPIVOTIDE TÉTRAXÉTAN
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550925131 flacon en verre de 7,5 mL Ã 12,5 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lutécium (177lu) vipivotide tétraxétan in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandPluvicto 1000 MBq/ml, Injektions-/InfusionslösungNovartis Pharma Schweiz AG
- United StatesPLUVICTONovartis Pharmaceuticals Corporation
- CzechiaPLUVICTONovartis Europharm Limited, Dublin
- FinlandPluvictoNovartis Europharm Limited
- BelgiumPluvicto 1000 MBq/mlNovartis Europharm
- IrelandPluvicto 1000 MBq/mL solution for injection/infusionNovartis Europharm Limited
- IcelandPluvictoNovartis Europharm Limited*
- NetherlandsPluvicto 1.000 MBq/ml oplossing voor injectie/infusieNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pluvicto
- Liechtenstein · Pluvicto
- Norway · Pluvicto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3939a508-9e7d-41bc-9879-181cc31881f5 GET /v1/drugs/3939a508-9e7d-41bc-9879-181cc31881f5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68234294",
"date_amm": "2022-12-09",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1703",
"substance": "LUTÉCIUM (177LU) VIPIVOTIDE TÉTRAXÉTAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable ou pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about lutécium (177lu) vipivotide tétraxétan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.